AUS
NZ
UK
CA
USA
IND
BioHarvest Sciences Inc. (OTC:CNVCF) has reported the resignation of David Ryan from his position as a director. Despite this change, Ryan will remain an integral part of the company's management team, continuing to fulfill his duties as vice president of investor relations.
The resignation aligns with Nasdaq's requirements, which stipulate that companies must have a majority of independent directors when applying for listing on the Nasdaq Stock Market. This move is part of BioHarvest’s ongoing efforts to enhance its corporate governance in accordance with regulatory standards.
Zaki Rakib, chair of the BioHarvest board, expressed appreciation for Ryan’s contributions during his tenure. Rakib acknowledged that Ryan's directorship has played a crucial role in the company's development. He emphasized that Ryan's cooperation during this transition reflects a commitment to the company's mission and its long-term vision.
The decision to step down as director does not diminish Ryan's influence within the organization. His experience and leadership in investor relations will continue to support BioHarvest’s initiatives and objectives. The company remains focused on its innovative projects and strategic goals, aiming to advance its position within the biotechnology sector.
BioHarvest has been making strides in its research and development efforts, with ongoing projects that leverage proprietary technology for the cultivation of plant-based products. The company is dedicated to advancing solutions that align with consumer health and wellness trends.
In summary, while the resignation of David Ryan from the board of directors marks a significant change, his continued role in investor relations is expected to contribute positively to BioHarvest’s mission. The company is committed to maintaining strong governance and is poised to navigate the challenges of becoming a publicly listed entity on the Nasdaq
